Rafael Holdings, Inc.: management transactions · United States · SEC (Form 4)

About Rafael Holdings, Inc.

Rafael Holdings, Inc. (NYSE: RFL) is a United States-listed company trading on the NYSE/NASDAQ market, with a business profile that sits squarely in healthcare and biotech. Headquartered in Newark, New Jersey, the company has evolved from a more asset-holding structure into a development-focused biopharmaceutical platform centered on novel therapeutics, especially oncology and rare-disease opportunities. Its corporate base in Newark anchors the group in the northeastern United States. ([rafaelholdings.com](https://rafaelholdings.com/?utm_source=openai)) The company’s operating model is built around a portfolio of controlled and majority-owned healthcare ventures. In its latest annual report, Rafael Holdings describes itself as a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage companies developing pharmaceuticals and medical devices. Its lead candidate is Trappsol® Cyclo™, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1, a rare, fatal, progressive genetic disorder. Rafael also holds interests in LipoMedix Pharmaceuticals, Barer Institute, and Cornerstone Pharmaceuticals, and it has recently brought Cyclo Therapeutics into its consolidated portfolio. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1713863/000121390025103549/ea0262395-10k_rafael.htm?utm_source=openai)) From a competitive standpoint, Rafael is best viewed as a small-cap biotech company whose valuation is driven less by current commercial revenues and more by clinical execution, intellectual property, and capital-market access. Its competitive position depends on advancing specialized programs through development milestones, generating meaningful trial data, and maintaining flexibility to support portfolio companies. This is a high-risk, high-upside profile typical of development-stage biotech issuers, where clinical readouts and regulatory progress can materially re-rate the stock. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1713863/000121390025103549/ea0262395-10k_rafael.htm?utm_source=openai)) Recent corporate updates have centered on fiscal 2025 results for the year ended July 31, 2025, where the company reported a smaller net loss than in the prior year, alongside higher R&D spending tied to new consolidated activities. Management also highlighted continued progress on Trappsol® Cyclo™ and the broader transition toward a more integrated biopharmaceutical enterprise. For French-speaking investors, Rafael Holdings should be monitored as a speculative U.S. healthcare name on the NYSE, with key catalysts coming from clinical updates, SEC Form 4 insider filings, financing actions, and portfolio-level transactions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1713863/000121390025103509/ea026292601ex99-1_rafael.htm?utm_source=openai))